Table 3.

Characteristics of discussed studies of rituximab in FSGS

Study	Study design	Population	Rituximab protocol	Selected outcomes	Results
Fernandez-Fresnedo et al26	Retrospective case series	Eight patients with FSGS resistant to steroids and other treatments, all patients had nephrotic range proteinuria at baseline with a mean of 14±4.4 g/24 h	Variable: five patients received 4 weekly doses at 375 mg/m2	24-hour proteinuria	Two patients had significant decrease in proteinuria to 3.2 and 3.9 g/day
			One patient received 4 weekly doses at 375 mg/m2 initially and again at month 12	Serum creatinine	One patient had transient decrease in proteinuria
			One patient received 4 weekly doses at 375 mg/m2 initially and 2 weekly infusions at month 6		Five patients failed to respond to rituximab therapy with no significant decrease in proteinuria
			One patient received 8 weekly doses at 375 mg/m2		Serum creatinine increased from 1.4±0.5 to 2.2±1.8 mg/dL
				Adverse events	No adverse events during follow-up
Ochi et al27	Case series	Two patients with steroid-resistant FSGS, and two patients with steroid- dependent FSGS	Single dose at 375 mg/m2	Complete remission (not defined in the manuscript)	CR achieved in the two patients with steroid-dependent FSGS
					The two patients with steroid-resistant FSGS did not respond to therapy
Ruggenenti et al28	Prospective, open-label, longitudinal, within-patient controlled study	30 patients (ten children, 20 adults) with steroid-dependent or frequently relapsing nephrotic syndrome (included eight patients with FSGS, five adults, three children)	Single dose at 375 mg/m2 (28 patients)	Number of relapse of nephrotic syndrome in the year after rituximab therapy vs the year before rituximab therapy	Fivefold decrease in number of relapse in all patients and in patients with FSGS
			Or two doses of rituximab (two patients)	Side effects	No treatment-related adverse events

Abbreviations: CR, complete remission; FSGS, focal and segmental glomerulosclerosis.